Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin.

MLA

Howroyd, Lucy-Rose, et al. “Pseudoprogression in Patients with Uterine Leiomyosarcoma Treated with First-Line Single-Agent Doxorubicin.” European Journal of Cancer, vol. 192, Oct. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.113261.

APA

Howroyd, L.-R., Cornell, I., Benson, C., Napolitano, A., Blackledge, M., Sumhonmun, T., Moskovic, E., Kelly-Morland, C., Adejolu, M., Jones, R. L., & Messiou, C. (2023). Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin. European Journal of Cancer, 192, N.PAG. https://doi.org/10.1016/j.ejca.2023.113261

Chicago

Howroyd, Lucy-Rose, Isabel Cornell, Charlotte Benson, Andrea Napolitano, Matthew Blackledge, Timothy Sumhonmun, Eleanor Moskovic, et al. 2023. “Pseudoprogression in Patients with Uterine Leiomyosarcoma Treated with First-Line Single-Agent Doxorubicin.” European Journal of Cancer 192 (October): N.PAG. doi:10.1016/j.ejca.2023.113261.